Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kura Oncology (KURA)

Kura Oncology (KURA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 759,667
  • Shares Outstanding, K 87,018
  • Annual Sales, $ 53,880 K
  • Annual Income, $ -173,980 K
  • EBIT $ -294 M
  • EBITDA $ -306 M
  • 60-Month Beta 0.23
  • Price/Sales 7.34
  • Price/Cash Flow N/A
  • Price/Book 3.10

Options Overview Details

View History
  • Implied Volatility 197.60% (+56.76%)
  • Historical Volatility 48.74%
  • IV Percentile 91%
  • IV Rank 37.23%
  • IV High 434.09% on 02/04/26
  • IV Low 57.32% on 08/18/25
  • Expected Move (DTE 20) 0.30 (3.41%)
  • Put/Call Vol Ratio 0.15
  • Today's Volume 91
  • Volume Avg (30-Day) 395
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 13,977
  • Open Int (30-Day) 14,428
  • Expected Range 8.43 to 9.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.72
  • Number of Estimates 6
  • High Estimate -0.09
  • Low Estimate -0.99
  • Prior Year -0.22
  • Growth Rate Est. (year over year) -227.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.36 +18.65%
on 02/05/26
8.76 -0.34%
on 02/27/26
+0.26 (+3.07%)
since 01/27/26
3-Month
7.36 +18.65%
on 02/05/26
12.32 -29.14%
on 12/04/25
-3.26 (-27.19%)
since 11/26/25
52-Week
5.41 +61.37%
on 04/07/25
12.49 -30.10%
on 11/14/25
+1.08 (+14.12%)
since 02/27/25

Most Recent Stories

More News
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today...

KURA : 8.73 (+0.92%)
Kura Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today...

KURA : 8.73 (+0.92%)
1 Under-$10 Stock Set to Surge as Much as 850% in 2026

Kura is a classic high-risk, high-reward biotech investment that has entered a vital growth phase.

KURA : 8.73 (+0.92%)
MRNA : 53.57 (+3.60%)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

KURA : 8.73 (+0.92%)
Record $2.5B Sector Start Spotlights Clinical Oncology Plays

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The global oncology market is surging toward $668.26 billion by 2034 with an 11.50% CAGR as innovative...

ALLO : 2.78 (+1.83%)
ONCY : 1.1300 (+5.61%)
IMNM : 21.86 (-0.14%)
LLY : 1,051.99 (+2.93%)
KURA : 8.73 (+0.92%)
AMGN : 388.16 (+2.33%)
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones

– Launched KOMZIFTI ™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million KOMZIFTI net product revenue for the...

KURA : 8.73 (+0.92%)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

KURA : 8.73 (+0.92%)
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML

– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS  – Median duration of complete response...

KURA : 8.73 (+0.92%)
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia

SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today...

KURA : 8.73 (+0.92%)
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin

SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...

KURA : 8.73 (+0.92%)

Business Summary

Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL,...

See More

Key Turning Points

3rd Resistance Point 9.07
2nd Resistance Point 8.92
1st Resistance Point 8.82
Last Price 8.73
1st Support Level 8.57
2nd Support Level 8.42
3rd Support Level 8.32

See More

52-Week High 12.49
Fibonacci 61.8% 9.79
Fibonacci 50% 8.95
Last Price 8.73
Fibonacci 38.2% 8.11
52-Week Low 5.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar